Vivos Therapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2024
Vivos Therapeutics Debt-to-Equity Ratio Growth & History (VVOS)
Vivos Therapeutics's debt-to-equity ratio was 0.34 for fiscal 2024.
View full Vivos Therapeutics company overviewVivos Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 0.34 | −7.43 | −95.61% |
| 2023 | 2023-12-31 | 7.77 | 7.27 | +1446.69% |
| 2022 | 2022-12-31 | 0.50 | 0.43 | +548.94% |
| 2021 | 2021-12-31 | 0.08 | 0.00 | +1.57% |
| 2020 | 2020-12-31 | 0.08 | — | — |
Vivos Therapeutics quarterly debt-to-equity ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | 4.94 | 4.57 | +1230.80% |
| Q2 2025 | 2025-06-30 | 2.53 | 2.06 | +441.11% |
| Q1 2025 | 2025-03-31 | 0.32 | −2.92 | −90.18% |
| Q4 2024 | 2024-12-31 | 0.34 | −7.43 | −95.61% |
| Q3 2024 | 2024-09-30 | 0.37 | −71.46 | −99.48% |
| Q2 2024 | 2024-06-30 | 0.47 | −1.15 | −71.17% |
| Q1 2024 | 2024-03-31 | 3.23 | 2.90 | +876.81% |
| Q4 2023 | 2023-12-31 | 7.77 | 7.27 | +1446.69% |
| Q3 2023 | 2023-09-30 | 71.83 | 71.54 | +24762.88% |
| Q2 2023 | 2023-06-30 | 1.62 | 1.42 | +726.48% |
| Q1 2023 | 2023-03-31 | 0.33 | 0.23 | +215.58% |
| Q4 2022 | 2022-12-31 | 0.50 | 0.43 | +548.94% |
| Q3 2022 | 2022-09-30 | 0.29 | 0.25 | +641.46% |
| Q2 2022 | 2022-06-30 | 0.20 | 0.16 | +465.09% |
| Q1 2022 | 2022-03-31 | 0.10 | 0.05 | +90.70% |
| Q4 2021 | 2021-12-31 | 0.08 | 0.00 | +1.57% |
| Q3 2021 | 2021-09-30 | 0.04 | — | — |
| Q2 2021 | 2021-06-30 | 0.03 | — | — |
| Q1 2021 | 2021-03-31 | 0.06 | — | — |
| Q4 2020 | 2020-12-31 | 0.08 | — | — |
Vivos Therapeutics debt-to-equity ratio trends
Between the periods ended 2020-12-31 and 2024-12-31, Vivos Therapeutics's debt-to-equity ratio increased from 0.08 to 0.34, a change of 0.26. The latest reported quarter, Q3 2025, shows 4.94.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗